Related Experiment Video
Updated: Jun 17, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha
Daniela Krejcová1, Jirina Procházková, Lukás Kubala
1Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Královopolská 135, 612 65 Brno, Czech Republic.
Abstract:
Treatments of non-small cell lung cancer (NSCLC), the most common form of lung cancer, still remain poor. Interferon alpha (IFN-alpha), an important physiological immunomodulator, possesses direct cytotoxic and cytostatic effects on tumour cells, antiangiogenic effects, and activates anti-tumour immunity. Recently, the IFN-alpha oncologic indications have included melanoma, renal carcinoma, and different types of leukaemia. However, the application of IFN-alpha in therapy of lung cancer has not been validated yet. Herein the human lung carcinoma cell line A549, a model of NSCLC in vitro, was used to pursue the effect of IFN-alpha on A549 cell proliferation and differentiation together with the effect on protein expression and activity of three ATP-transporters mediating multi-drug resistance (MDR). IFN-alpha significantly inhibited the proliferation of A549 cells which was not connected with arrest in a particular cell cycle phase. Further, IFN-alpha-mediated differentiation of A549 was observed based on an increase in alkaline phosphatase activity. Simultaneously, IFN-alpha increased the expression and activity of ATP-transporters mediating MDR. Thus, the IFN-alpha down-regulation of NSCLC cell proliferation was accompanied by a potential of cells to exclude potential therapeutic substances such as chemotherapeutic agents. These effects could have a significant impact on considerations of IFN-alpha as a therapeutic agent for NSCLC.
Insights
Interferon alpha (IFN-alpha) inhibits non-small cell lung cancer (NSCLC) cell proliferation and promotes differentiation. However, it also increases multi-drug resistance (MDR) transporters, potentially limiting chemotherapy efficacy in NSCLC treatment.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Non-small cell lung cancer (NSCLC) treatments have limited efficacy.
- Interferon alpha (IFN-alpha) is an immunomodulator with anti-cancer properties, but its use in lung cancer is unproven.
- Multi-drug resistance (MDR) is a significant challenge in NSCLC therapy.
Purpose of the Study:
- To investigate the effects of IFN-alpha on NSCLC cell proliferation, differentiation, and MDR.
- To evaluate the potential of IFN-alpha as a therapeutic agent for NSCLC.
Main Methods:
- Utilized the A549 human lung carcinoma cell line as an in vitro model for NSCLC.
- Assessed the impact of IFN-alpha on cell proliferation, cell cycle, alkaline phosphatase activity (differentiation marker), and protein expression/activity of MDR-associated ATP-transporters.
Main Results:
- IFN-alpha significantly inhibited A549 cell proliferation without causing cell cycle arrest.
- IFN-alpha induced A549 cell differentiation, evidenced by increased alkaline phosphatase activity.
- IFN-alpha upregulated the expression and activity of ATP-transporters involved in MDR.
Conclusions:
- IFN-alpha demonstrates anti-proliferative and differentiation-inducing effects on NSCLC cells.
- The concurrent increase in MDR transporters suggests that IFN-alpha may enhance the drug-efflux capacity of NSCLC cells.
- These findings highlight a potential dual effect of IFN-alpha in NSCLC, necessitating careful consideration for its therapeutic application.
